Study protocol for pragmatic trials of Internet-delivered guided and unguided cognitive behavior therapy for treating depression and anxiety in university students of two Latin American countries: the Yo Puedo Sentirme Bien study.
Anxiety
College students
Depression
Latin America
Precision treatment algorithm
iCBT
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
02 Jun 2022
02 Jun 2022
Historique:
received:
16
06
2021
accepted:
29
03
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are highly prevalent among university students and predict impaired college performance and later life role functioning. Yet most students do not receive treatment, especially in low-middle-income countries (LMICs). We aim to evaluate the effects of expanding treatment using scalable and inexpensive Internet-delivered transdiagnostic cognitive behavioral therapy (iCBT) among college students with symptoms of MDD and/or GAD in two LMICs in Latin America (Colombia and Mexico) and to investigate the feasibility of creating a precision treatment rule (PTR) to predict for whom iCBT is most effective. We will first carry out a multi-site randomized pragmatic clinical trial (N = 1500) of students seeking treatment at student mental health clinics in participating universities or responding to an email offering services. Students on wait lists for clinic services will be randomized to unguided iCBT (33%), guided iCBT (33%), and treatment as usual (TAU) (33%). iCBT will be provided immediately whereas TAU will be whenever a clinic appointment is available. Short-term aggregate effects will be assessed at 90 days and longer-term effects 12 months after randomization. We will use ensemble machine learning to predict heterogeneity of treatment effects of unguided versus guided iCBT versus TAU and develop a precision treatment rule (PTR) to optimize individual student outcome. We will then conduct a second and third trial with separate samples (n = 500 per arm), but with unequal allocation across two arms: 25% will be assigned to the treatment determined to yield optimal outcomes based on the PTR developed in the first trial (PTR for optimal short-term outcomes for Trial 2 and 12-month outcomes for Trial 3), whereas the remaining 75% will be assigned with equal allocation across all three treatment arms. By collecting comprehensive baseline characteristics to evaluate heterogeneity of treatment effects, we will provide valuable and innovative information to optimize treatment effects and guide university mental health treatment planning. Such an effort could have enormous public-health implications for the region by increasing the reach of treatment, decreasing unmet need and clinic wait times, and serving as a model of evidence-based intervention planning and implementation. IRB Approval of Protocol Version 1.0; June 3, 2020. Recruitment began on March 1, 2021. Recruitment is tentatively scheduled to be completed on May 30, 2024. ClinicalTrials.gov NCT04780542 . First submission date: February 28, 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are highly prevalent among university students and predict impaired college performance and later life role functioning. Yet most students do not receive treatment, especially in low-middle-income countries (LMICs). We aim to evaluate the effects of expanding treatment using scalable and inexpensive Internet-delivered transdiagnostic cognitive behavioral therapy (iCBT) among college students with symptoms of MDD and/or GAD in two LMICs in Latin America (Colombia and Mexico) and to investigate the feasibility of creating a precision treatment rule (PTR) to predict for whom iCBT is most effective.
METHODS
METHODS
We will first carry out a multi-site randomized pragmatic clinical trial (N = 1500) of students seeking treatment at student mental health clinics in participating universities or responding to an email offering services. Students on wait lists for clinic services will be randomized to unguided iCBT (33%), guided iCBT (33%), and treatment as usual (TAU) (33%). iCBT will be provided immediately whereas TAU will be whenever a clinic appointment is available. Short-term aggregate effects will be assessed at 90 days and longer-term effects 12 months after randomization. We will use ensemble machine learning to predict heterogeneity of treatment effects of unguided versus guided iCBT versus TAU and develop a precision treatment rule (PTR) to optimize individual student outcome. We will then conduct a second and third trial with separate samples (n = 500 per arm), but with unequal allocation across two arms: 25% will be assigned to the treatment determined to yield optimal outcomes based on the PTR developed in the first trial (PTR for optimal short-term outcomes for Trial 2 and 12-month outcomes for Trial 3), whereas the remaining 75% will be assigned with equal allocation across all three treatment arms.
DISCUSSION
CONCLUSIONS
By collecting comprehensive baseline characteristics to evaluate heterogeneity of treatment effects, we will provide valuable and innovative information to optimize treatment effects and guide university mental health treatment planning. Such an effort could have enormous public-health implications for the region by increasing the reach of treatment, decreasing unmet need and clinic wait times, and serving as a model of evidence-based intervention planning and implementation.
TRIAL STATUS
METHODS
IRB Approval of Protocol Version 1.0; June 3, 2020. Recruitment began on March 1, 2021. Recruitment is tentatively scheduled to be completed on May 30, 2024.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04780542 . First submission date: February 28, 2021.
Identifiants
pubmed: 35658942
doi: 10.1186/s13063-022-06255-3
pii: 10.1186/s13063-022-06255-3
pmc: PMC9164185
doi:
Banques de données
ClinicalTrials.gov
['NCT04780542']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
450Subventions
Organisme : NIMH NIH HHS
ID : R01 MH120648
Pays : United States
Organisme : NIMH NIH HHS
ID : R01MH120648
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Int J Methods Psychiatr Res. 2019 Jun;28(2):e1764
pubmed: 30663193
Br J Psychiatry. 2017 Feb;210(2):119-124
pubmed: 27908899
J Affect Disord. 2004 Feb;78(2):131-40
pubmed: 14706723
J Med Internet Res. 2021 Mar 24;23(3):e24387
pubmed: 33759801
Clin Psychol Rev. 2015 Jun;38:39-54
pubmed: 25795293
J Med Internet Res. 2006 Nov 14;8(4):e27
pubmed: 17213046
Epidemiology. 2019 May;30(3):334-341
pubmed: 30789432
Stat Methods Med Res. 2017 Aug;26(4):1630-1640
pubmed: 28482779
Int J Biostat. 2016 May 1;12(1):97-115
pubmed: 26226129
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
JMIR Ment Health. 2018 Dec 14;5(4):e11467
pubmed: 30552076
World Psychiatry. 2017 Oct;16(3):299-307
pubmed: 28941090
Psychol Med. 2013 Aug;43(8):1625-37
pubmed: 23075829
Depress Anxiety. 2018 Feb;35(2):122-131
pubmed: 29095544
Lancet. 2011 Mar 26;377(9771):1113-21
pubmed: 21074256
Epidemiol Psychiatr Sci. 2017 Feb;26(1):22-36
pubmed: 26810628
Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31
pubmed: 26719105
Perspect Clin Res. 2011 Jul;2(3):109-12
pubmed: 21897887
Behav Res Ther. 2019 Sep;120:103412
pubmed: 31233922
Psychiatr Q. 2016 Sep;87(3):445-64
pubmed: 26563229
Am J Psychiatry. 2011 Dec;168(12):1266-77
pubmed: 22193671
Asian J Psychiatr. 2013 Aug;6(4):318-23
pubmed: 23810140
J Psychiatr Res. 2013 Mar;47(3):391-400
pubmed: 23260171
Biometrics. 2015 Dec;71(4):1160-7
pubmed: 26149119
Lancet Psychiatry. 2020 Oct;7(10):851-864
pubmed: 32866459
Psychol Med. 2016 Oct;46(14):2955-2970
pubmed: 27484622
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Mol Psychiatry. 2020 Jan;25(1):168-179
pubmed: 31570777
Psychosom Med. 2016 Jul-Aug;78(6):716-27
pubmed: 27187854
Harv Rev Psychiatry. 2017 May/Jun;25(3):114-122
pubmed: 28475503
Ann Intern Med. 2017 Jul 4;167(1):40-47
pubmed: 28630973
J Affect Disord. 2010 Dec;127(1-3):122-9
pubmed: 20569992
Annu Rev Clin Psychol. 2018 May 7;14:209-236
pubmed: 29494258
Glob Ment Health (Camb). 2015 Jul 14;2:e12
pubmed: 28596860
Psychiatr Clin North Am. 2010 Sep;33(3):537-55
pubmed: 20599132
Int J Methods Psychiatr Res. 2007;16(2):52-65
pubmed: 17623385
Int J Methods Psychiatr Res. 2019 Jun;28(2):e1752
pubmed: 30450753
J Med Internet Res. 2019 Aug 01;21(8):e12775
pubmed: 31373272
Depress Anxiety. 2019 Sep;36(9):790-800
pubmed: 31356709
Eur J Psychotraumatol. 2019 Aug 27;10(1):1646092
pubmed: 31497259
World Psychiatry. 2020 Oct;19(3):269-293
pubmed: 32931110
Int J Methods Psychiatr Res. 2004;13(2):93-121
pubmed: 15297906
J Trauma Stress. 2007 Dec;20(6):1019-28
pubmed: 18157881
Internet Interv. 2019 Jan 14;15:76-86
pubmed: 30740313
Int J Methods Psychiatr Res. 2019 Jun;28(2):e1759
pubmed: 30585363
Psychiatr Clin North Am. 2017 Dec;40(4):675-687
pubmed: 29080593
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
Internet Interv. 2021 May 05;25:100400
pubmed: 34026569
Hum Psychopharmacol. 2016 Jan;31(1):53-63
pubmed: 26331440
Int J Methods Psychiatr Res. 2019 Jun;28(2):e1756
pubmed: 30614124
J Affect Disord. 2006 Dec;96(3):259-69
pubmed: 16997383
Depress Anxiety. 2018 Mar;35(3):195-208
pubmed: 29356216
PLoS One. 2014 Jan 08;9(1):e83875
pubmed: 24416178
Stat Appl Genet Mol Biol. 2007;6:Article25
pubmed: 17910531
J Med Internet Res. 2018 Apr 23;20(4):e136
pubmed: 29685870
Stat Med. 2014 Jun 15;33(13):2297-340
pubmed: 24599889
JAMA Psychiatry. 2021 Apr 1;78(4):361-371
pubmed: 33471111
Int J Biostat. 2016 May 1;12(1):305-32
pubmed: 27227726
J Clin Psychiatry. 2017 Feb;78(2):177-183
pubmed: 28234434
Int J Methods Psychiatr Res. 2019 Jun;28(2):e1750
pubmed: 30402985
J Med Internet Res. 2020 Oct 28;22(10):e17049
pubmed: 33112238
Pharm Stat. 2016 Nov;15(6):494-506
pubmed: 27658505
Med Educ. 2016 Aug;50(8):842-51
pubmed: 27402044
Psychol Assess. 2007 Sep;19(3):309-17
pubmed: 17845122
JMIR Ment Health. 2020 Jan 31;7(1):e13392
pubmed: 32003749
Psychol Med. 2011 Nov;41(11):2239-52
pubmed: 21672297
Int J Methods Psychiatr Res. 2019 Jun;28(2):e1762
pubmed: 30623516
Front Psychiatry. 2019 Sep 13;10:664
pubmed: 31572242
Clin Psychol Rev. 2011 Feb;31(1):89-103
pubmed: 21130939
PLoS One. 2016 May 02;11(5):e0154248
pubmed: 27135410
Drug Alcohol Rev. 2018 Jan;37(1):79-86
pubmed: 28480521
Front Psychiatry. 2020 Jan 09;10:902
pubmed: 31998149
NPJ Digit Med. 2020 Jun 15;3:85
pubmed: 32566763
Curr Opin Psychiatry. 2018 Jan;31(1):32-39
pubmed: 29076894
Int J Methods Psychiatr Res. 2013 Dec;22(4):303-21
pubmed: 24318219
Glob Health Sci Pract. 2018 Mar 30;6(1):82-92
pubmed: 29602867
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Depress Anxiety. 2017 Jul;34(7):596-602
pubmed: 28471479